Effectiveness and Safety of Zercepac and Reference Trastuzumab in the Neoadjuvant Setting for Early-Stage Breast Cancer: A Retrospective Cohort Study

AIM: Since the high cost of reference trastuzumab limits its clinical application, this study aimed to compare the effectiveness and safety of the Zercepac and reference product trastuzumab in neoadjuvant therapy for HER2-positive breast cancer. METHODS: This study retrospectively collected clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zheying, Guan, Yinan, Yao, Yongzhong, Zhang, Weijie, Zhuang, Xiaoming, Zhang, Yin, Zhu, Tingting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649327/
https://www.ncbi.nlm.nih.gov/pubmed/36385963
http://dx.doi.org/10.1155/2022/9998114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649327/
https://www.ncbi.nlm.nih.gov/pubmed/36385963
http://dx.doi.org/10.1155/2022/9998114

Ejemplares similares